|
1. Biologie
|
|
|
By forming clots in tumors, immune cells aid lung cancer's spread [UNC]
|
|
|
|
|
|
In
the journal Nature Communications, researchers report for a particular
subset of lung cancer tumors, there is a high prevalence of immune cells
called inflammatory monocytes. These immune cells, which normally help
to build clotting scaffolds to promote wound healing, also make it
possible for tumor cells to migrate and spread to other parts of the
body.
|
|
|
|
|
|
|
NIH study finds gut microbiome can control antitumor immune function in liver [NIH]
|
|
|
|
|
|
To
investigate whether gut bacteria affect the development of tumors in
the liver, Dr. Greten and his team carried out a series of experiments
with mice. They used three mouse models of liver cancer, and found that
when they depleted gut bacteria using an antibiotic “cocktail,” the mice
that had the antibiotics developed fewer and smaller liver tumors and
had reduced metastasis to the liver.
|
|
|
|
|
|
|
2. Etiologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Tau Mutations May Increase Cancer Risk [AACR]
|
|
|
|
|
|
Tagliavini
and colleagues analyzed cancer incidence in 15 families bearing seven
different tau mutations and affected by FTLD (frontotemporal lobar
degeneration). To calculate cancer risk, each tau-mutated family was
matched with three reference families with superimposable pedigrees
(control subject’s age, gender, and native location matching the person
affected with FTLD).
|
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Breast screen error 'could have been spotted earlier' [BBC News]
|
|
|
|
|
|
Prof
Sasieni, who is also lead investigator of the Cancer Research UK
programme in cancer screening and statistics, said: "Data that could
have alerted people to the lack of invitations being sent to women aged
70 was publicly available, but no one looked at it carefully enough."
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
A Closed Loop [in the Pipeline]
|
|
|
|
|
|
A
collaboration between the University of Helsinki, LifeArc (which looks
to be one of the small companies in the former Stevenage pharma campus)
and Cyclofluidic reports development of inhibitors against hepsin, a
serine protease enzyme that is a potential cancer target.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5.1 ASCO (général)
|
|
|
|
5.5.1.2 ASCO (général) - Académiques
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
Physical Activity in Cancer Survivors During “Re-Entry” Following Cancer Treatment [CDC]
|
|
|
|
|
|
The
transition from active cancer treatment into survivorship, known as
re-entry, remains understudied. During re-entry, clinicians can educate
survivors on the benefits of healthy behaviors, including physical
activity, as survivors adjust to life after cancer. We examine the
prevalence of adherence to established aerobic physical activity
guidelines (≥150 minutes of moderate-intensity physical activity per
week) in addition to related medico-demographic factors among cancer
survivors during re-entry.
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
Right To Try Act Poses Big Challenge For FDA [NPR]
|
|
|
|
|
|
Given
the version of right-to-try legislation headed for President Trump's
signature, it remains unclear exactly how Gottlieb will address the
agency's earlier concerns. The main issue is that the Right to Try Act
is intended to run parallel to the FDA's expanded access pathway,
providing a route for patients to circumvent the agency.
|
|
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|
|
|
6.9 Controverses
|
|
|
|
Why was Theranos so believable? Medicine needs to look in the mirror [STAT]
|
|
|
|
|
|
Did
the claims made by Theranos stand out as that outrageous, unbelievable,
or in need of extra scrutiny? Not when you measure it by a few examples
of standout hype I have collected over the years. Who can forget when
James Watson, the legendary yet now disgraced co-discoverer of the DNA
double helix, made a prediction in 1998 to the New York Times that
so-called VEGF inhibitors would cure cancer in “two years”?
|
|
|
|
|
|